80 patents
Page 3 of 4
Utility
Heterocyclic RIP1 Inhibitory Compounds
13 May 21
Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
Filed: 6 Nov 20
Utility
TGF-SS Inhibitors
6 May 21
Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
Filed: 2 Nov 20
Utility
Tyrosine Kinase Inhibitors
18 Mar 21
Ihab Darwish, Jiaxin Yu, Rao Kolluri, Sacha Holland
Filed: 25 Nov 20
Utility
Nrf2 Activating Compounds and Uses Thereof
18 Mar 21
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 20 Oct 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
11 Mar 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
Filed: 4 Sep 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
11 Mar 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP 1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Jiaxin Yu, Ihab Darwish, Vanessa Taylor, Rao Kolluri, Yan Chen, Simon Shaw, Somasekhar Bhamidipati, Zhushou Luo
Filed: 4 Sep 20
Utility
Heterocyclic RIP1 Kinase Inhibitors
11 Mar 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor
Filed: 4 Sep 20
Utility
Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds And/or Formulations
4 Mar 21
Lu Chou, Matt Duan, Ihab Darwish, Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor, Yan Chen, Dazhong Fan, Zhushou Luo
Filed: 28 Aug 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
11 Feb 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 16 Oct 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
14 Jan 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 16 Sep 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
6 Jan 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 15 Sep 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
6 Jan 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 15 Sep 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
30 Dec 20
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 15 Sep 20
Utility
Method of Preventing and Treating Thrombosis
2 Dec 20
A method of preventing or treating thrombosis in a patent is disclose, wherein the method comprises administering to the patient an amount of fostamatinib or a form or metabolite thereof effective to prevent or treat the thrombosis, respectively.
Esteban Masuda
Filed: 28 May 20
Utility
Prodrugs of Nrf2 Activating Compounds and Uses Thereof
25 Nov 20
Aspects of the present disclosure include prodrugs of compounds that activate Nrf2.
Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
Filed: 11 Aug 20
Utility
Benzazole Compounds and Methods for Making and Using the Compounds
28 Oct 20
Disclosed are novel benzazole compounds and compositions comprising the compounds.
Rose Yen, Yan Chen, Rajinder Singh, Vanessa Taylor
Filed: 13 Jul 20
Utility
Nrf2 Activating Compounds and Uses Thereof
28 Oct 20
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 1 Apr 20
Utility
Antigen Binding Molecules to Tigit
28 Oct 20
Provided herein are antigen binding molecules that bind to TIGIT, including antibodies and antigen binding fragments thereof.
Ramesh R. Bhatt, Todd Kinsella, Wei Li
Filed: 9 Jul 20
Utility
2,4-DIAMINO-PYRIMIDINE Compounds and Method for Making and Using the Compounds
23 Sep 20
Yan Chen, Rose Yen, Jiaxin Yu, Vanessa Taylor, Rajinder Singh
Filed: 4 Jun 20
Utility
Prodrugs of 2,4-PYRIMIDINEDIAMINE Compounds and Their Uses
26 Aug 20
The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda, Thomas Sun, Valentino J. Stella
Filed: 1 Mar 20